Physician

Ahmed Abdel Mekkawy, M.D.

According to 2025 Medicare claims, Ahmed Mekkawy, M.D. (NPI: 1033181680) practices pulmonary disease in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Passaic, NJ. This provider's primary affiliated billing organization is AHMED MEKKAWY, M.D., P.A. (NPI: 1891097648) and primary practice location at 07013-2724.

Mekkawy's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 503 traditional Medicare patients, billed 3,545 HCPCS/CPT codes, and received $229,692 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 4,862 prescription claims across 459 beneficiaries totaling $2,262,770 in drug costs, led by Opsumit (Macitentan). DME data shows 891 claims. Open Payments data shows 48 records totaling $2,366. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $502,609 to $229,692. In contrast, Part D prescription costs have moved sharply higher in recent years, from $831,101 to $2,262,770. For DME billing, this smaller-volume category did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	835	8,806	$502,609
2016	843	9,055	$491,766
2017	777	8,063	$400,948
2018	710	7,865	$407,303
2019	697	7,219	$391,911
2020	568	5,371	$288,148
2021	522	5,033	$287,171
2022	515	4,620	$273,300
2023	514	4,028	$254,742
2024	503	3,545	$229,692

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	396	4,541	$831,101
2016	426	4,332	$830,767
2017	421	4,059	$734,310
2018	438	4,008	$764,118
2019	428	3,999	$792,488
2020	421	4,089	$1,099,457
2021	401	4,018	$1,583,051
2022	417	4,175	$2,043,453
2023	423	4,337	$2,333,509
2024	459	4,862	$2,262,770

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	203	1,103	$92,453
2016	267	1,091	$68,076
2017	268	1,227	$80,112
2018	301	1,329	$97,658
2019	274	1,236	$89,785
2020	259	1,125	$70,502
2021	207	932	$59,867
2022	237	963	$71,434
2023	207	999	$63,414
2024	240	891	$49,619

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	339	605	$103
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	377	1,018	$70
G0008	Administration of influenza virus vaccine	170	170	$35
36415	Insertion of needle into vein for collection of blood sample	188	562	$9
94640	Inhalation treatment for airway obstruction or sputum production	172	227	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Opsumit	Macitentan	62	1,890	$790,572
Ofev	Nintedanib Esylate	31	930	$429,626
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	372	18,870	$386,763
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	117	5,610	$114,312
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	123	5,910	$87,358

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	12	$12,032
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	14	83	$6,188
J7606	Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms	N	N/R	26	$5,501
E0601	Continuous positive airway pressure (cpap) device	Y	20	113	$3,146
A7034	Nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap	N	31	61	$2,955

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	48	$2,366	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ahmed Abdel Mekkawy, M.D.?

Tedicare shows public-source Medicare data for Ahmed Abdel Mekkawy, M.D. (NPI 1033181680), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ahmed Abdel Mekkawy, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ahmed Abdel Mekkawy, M.D.?

Ahmed Abdel Mekkawy, M.D. is linked to AHMED MEKKAWY, M.D., P.A. (billing NPI 1891097648) in the available physician profile data.

Does Ahmed Abdel Mekkawy, M.D. have Open Payments data?

Ahmed Abdel Mekkawy, M.D. has 48 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.